Table 6.
Prevalence of consumption amongst 18–35-year-olds.
| 18–35 Years | |||||||
|---|---|---|---|---|---|---|---|
| Country | Survey | Age Range (Years) | Years | Measure | Prevalence (%) | % Change | Trend |
| US | Behavioral Risk Factor Surveillance System (Grucza et al., 2018) |
18–29 | 2002–2013 | Past month | T: 60.5–56.1 | −4.4 | ↔ |
| Monitoring the Futurea | 19–30 | 2000–2015 (Twenge & Park, 2019) | Lifetimeb | T: 89.5–86 | −3.5 | ↔ | |
| 23–26 | 2000–2019 (Schulenberg et al., 2020) |
Past month | M: 76.2–74.9 F: 65.8–74.1 |
−1.3 +8.3 |
M: ↔ F: ↗ |
||
| 25–26 | Past month | T: 68.7–75.0 | +6.3 | ↗ | |||
| Past year | T: 84.2–87.8 | +3.6 | ↔ | ||||
| National Alcohol Survey (Grucza et al., 2018) | 18–29 | 2000–2010c | Past yeard | T: 69.3–75.3 | +6.0 | ↗ | |
| National Epidemiological Survey on Alcohol and Related Conditions (Grant et al., 2017; Grucza et al., 2018) | 18–29 | 2001/2–2012/3 | Past month | T: 73.1–80.1 | +7.0 | ↗ | |
| National Health and Nutrition Examination Survey (Grucza et al., 2018) |
18–29 | 2001/2–2013/4 | Past yeard | T: 75.7–80.1 | +4.4 | ↔ | |
| National Health Interview Survey | 18–29 | 2002–2013 (Grucza et al., 2018) |
Past year | T: 65.1d–68.3d | +3.2 | ↔ | |
| 2006–2018 (McKetta & Keyes, 2019) | M: 73–72 F: 61–70 |
−1.0 +9.0 |
M: ↔ F: ↗ |
||||
| National Survey on Drug Use and Health | 18–29 (Grucza et al., 2018) |
2002–2012 | Past year | T: 78.2–78.7 | +0.5 | ↔ | |
| UK (England) | Health Survey for England (NHS Digital, 2020) | 25–34 | 2000–2019 | Past weeke | T: 72–51 M: 77–57 F: 67–45 |
−21.0 −20.0 −21.0 |
↘ |
| UK (Scotland) | Scottish Health Survey** | 25–34 | 2008–2019 (Scottish Health Survey, 2020; The Scottish Government, 2009) |
Past year | T: 90–88 | −2.0 | T: ↔ M: ↔ F: ↘ |
| 2003–2019 (Bromley et al., 2008; Scottish Health Survey, 2020) | M: 93 to 92 F: 90 to 84 |
−1.0 −6.0 |
|||||
| Ireland | Irish National Drug and Alcohol Survey (Mongan et al., 2021) | 25–34 | 2002/3–2019/20 | Past year | T: 91.0–81.3 | −9.7 | ↘ |
| Australia | Australian National Health Survey (Australian Bureau of Statistics, 2002, 2017–18) | 25–34 | 2001–2017/18 | Past weekf | T: 63.2–52.1 M: 73.0–61.3 F: 53.7–43.5 |
−11.1 −11.7 −10.2 |
↘ |
| Past yearf | T: 87.3–80.4 M: 90.0–88.3 F: 84.7–73.3 |
−6.9 −1.7 −11.4 |
T: ↘ M: ↔ F: ↘ |
||||
| Lifetimee,f | T: 92.5–88.4 M: 93.9–92.6 F: 91.2–83.8 |
−4.1 −1.3 −7.4 |
T: ↔ M: ↔ F: ↘ |
||||
| National Drug Strategy Household Survey | 18–29 | 2001–2013 (Callinan et al., 2017) | Lifetime | T: 87.0–79.0 | −8.0 | ↘ | |
| 20–29 | 2001–2019 | Past year | T: 91.1–78.0 (AIHW, 2020) |
−12.1 | |||
| 25–29 | T: 91.2–76.4 (AIHW, 2021) |
−14.8 | |||||
| 2001–2013 (Livingston, 2015) |
Lifetime | T: 95.9–89.2 | −6.7 | ||||
| New Zealand | New Zealand Health Survey | 25–34 | 2006/7–2018/19 (Ministry of Health, n.d.) |
Past year | T: 86.7–82.3 | −4.8 | ↔ |
Key: ↗: Increase of >5.0% between the start and end point provided. ↘: Decrease of >5.0% between the start and end point provided. ↔: Stable – any value with an increase or decrease of ≤5% between the start and end point provided. US: United States; UK: United Kingdom; T: total; M: male; F: female.
Monitoring the Future consists of a cross-sectional survey in 12th grade, with participants then selected to continue in a “panel” survey. This therefore has both cross-sectional and cohort elements.
Figure obtained from a graph.
Estimates are based on the fitted trend line for each survey, using all years of available data. These results were used to calculate the predicted average prevalence for each survey and each subgroup for the years 2002 and 2013.
Note that the National Alcohol Survey takes place approximately every 5 years (2000, 2005, 2009/10, etc) and so did not have surveys in 2002 and 2013. The data here is based on a fitted trend line using all years of available data.
Reported in record as abstention data.
Author-calculated value based on data available in the original record.